BTIG Research Reaffirms “Neutral” Rating for MDxHealth (NASDAQ:MDXH)

MDxHealth (NASDAQ:MDXH)‘s stock had its “neutral” rating restated by equities researchers at BTIG Research in a report released on Monday, Marketbeat.com reports.

A number of other research firms have also recently issued reports on MDXH. Lake Street Capital cut MDxHealth from a “buy” rating to a “hold” rating and set a $0.50 target price for the company. in a research note on Friday, October 16th. Weiss Ratings downgraded MDxHealth from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, September 8th. Craig Hallum lowered MDxHealth from a “buy” rating to a “hold” rating in a research report on Friday, October 16th. Finally, Wall Street Zen upgraded MDxHealth to a “sell” rating in a research note on Saturday, August 15th. One equities research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $1.33.

MDxHealth Trading Up 6.1%

NASDAQ:MDXH opened at $0.19 on Monday. The stock has a market capitalization of $9.62 million, a P/E ratio of -0.27 and a beta of 1.68. MDxHealth has a 1 year low of $0.17 and a 1 year high of $5.33. The firm has a 50 day moving average of $0.63 and a 200-day moving average of $0.88.

MDxHealth (NASDAQ:MDXH) last announced its earnings results on Friday, August 14th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01. The company had revenue of $27.21 million during the quarter, compared to the consensus estimate of $26.14 million. As a group, analysts forecast that MDxHealth will post -0.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of MDXH. Squarepoint Ops LLC bought a new position in MDxHealth during the second quarter worth $82,000. Bank of America Corp DE increased its holdings in shares of MDxHealth by 213.9% in the first quarter. Bank of America Corp DE now owns 43,492 shares of the company’s stock valued at $100,000 after purchasing an additional 29,638 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of MDxHealth by 21.8% in the first quarter. Renaissance Technologies LLC now owns 304,700 shares of the company’s stock valued at $701,000 after purchasing an additional 54,600 shares during the period. Finally, Perkins Capital Management Inc. raised its position in shares of MDxHealth by 7.1% in the first quarter. Perkins Capital Management Inc. now owns 1,476,441 shares of the company’s stock valued at $3,396,000 after purchasing an additional 97,500 shares during the period.

About MDxHealth

MDxHealth is a precision diagnostics company focused on improving the detection, diagnosis and management of cancer. The company develops and commercializes molecular and genomic tests designed to help physicians assess cancer risk, guide treatment decisions and monitor patients, with a primary focus on urological cancers.

Its product portfolio includes ConfirmMDx, a tissue-based test intended to help identify men who may have clinically significant prostate cancer after a prior negative biopsy; SelectMDx, a urine-based test that helps assess the likelihood of clinically significant prostate cancer; and ResolveMDx, a molecular test designed to support prostate cancer risk assessment.